| Business Summary | | Columbia
Laboratories,
Inc.
develops
pharmaceutical
products
that
treat
female
specific
diseases
and
conditions
including
infertility,
dysmenorrhea,
endometriosis
and
hormonal
deficiencies.
Columbia's
research
in
endocrinology
has
also
led
to
the
development
of
a
product
to
treat
Andropause
in
men.
Columbia's
products
primarily
utilize
the
Company's
patented
bioadhesive
delivery
technology,
the
Bioadhesive
Delivery
System.
Formulated
products
utilizing
the
Bioadhesive
Delivery
System
consist
principally
of
a
polymer,
polycarbophil
and
an
active
ingredient.
The
Bioadhesive
Delivery
System
is
based
upon
the
principle
of
bioadhesion,
a
process
by
which
the
polymer
adheres
to
epithelial
surfaces
and
to
mucin,
a
naturally
occurring
secretion
of
the
mucous
membranes. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | COB
develops
pharmaceutical
products
for
female
diseases
including
infertility,
hormonal
deficiencies,
dysmenorrhea,
endometriosis,
and
STD
using
patented
bio-adhesive
delivery
technology.
For
the
six
months
ended
6/30/01,
sales
fell
78%
to
$1.3
million.
Net
loss
applicable
to
Common
totaled
$8.4
million,
up
from
$2.7
million.
Revenues
reflect
lower
sales
of
Crinone.
Higher
loss
also
reflects
the
costs
associated
with
Phase
III
trials
and
product
recalls. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| William Bologna, 58 Chairman | $400K | -- | G. Frederick Wilkinson, 45 Pres,
CEO | -- | -- | James Apostolakis, 58 Vice
Chairman | 200K | -- | David Weinberg, 55 VP-
Fin. and Admin., CFO, Sec. and Treasurer | 200K | -- | Dominique De Ziegler, 53 VP-
Pharmaceutical Devel. | 210K | $600K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|